No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AXGN240719C5000
- 4.61
- +1.68+57.34%
15min DelayClose Jul 19 16:00 ET
4.61High4.61Low
4.61Open2.93Pre Close1 Volume1 Open Interest5.00Strike Price461.00Turnover6337.38%IV5.37%PremiumJul 19, 2024Expiry Date4.12Intrinsic Value100Multiplier-2DDays to Expiry0.49Extrinsic Value100Contract SizeAmericanOptions Type0.8972Delta0.0310Gamma2.03Leverage Ratio-14.2493Theta0.0000Rho1.82Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
AxoGen Insiders Sold US$639k Of Shares Suggesting Hesitancy
A number of AxoGen, Inc. (NASDAQ:AXGN) insiders sold their shares in the last year, which may have raised concerns among investors. Knowing whether insiders are buying is usually more helpful when
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
Express News | AxoGen Inc : Raymond James Initiates Coverage With Outperform Rating; Target Price $13
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an
Raymond James Initiates AxoGen(AXGN.US) With Buy Rating, Announces Target Price $13
Raymond James analyst Jayson Bedford initiates coverage on $AxoGen(AXGN.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 64.2% and
Axogen Initiated at Outperform by Raymond James
Axogen Initiated at Outperform by Raymond James
Comments
Cantor Fitzgerald sees AVITA's superior growth and high gross margins as reasons for a premium. The firm also sees potential in Pacific Biosciences and AxoGen, and expects positive share price appreciation for Exagen and NeuroPace. A significant catalyst for Nyxoah's stock is anticipated with upcoming DREAM study data.
Cantor Picks RCEL as Best 2024 Medtech Idea; Bullish on PACB, AXGN, CERSAxoGen's EBIT loss and debt levels could strain its balance sheet despite its US$368.0m market cap. While revenue is growing, its financial performance is considered slow.
CEO of Axogen, Karen Zaderej is excited for Kathy Weiler to use her vast commercial knowledge to aid the company's goal of becoming cash flow positive. Weiler herself is equally fired up to be able to aid in Axogen's commercial success.
The recent insider selling, despite small insider buying in AxoGen, raises concerns on the stock. Despite the reasonably high level of insider ownership, the history of sales makes the investment prospect less attractive in the immediate term.
$AxoGen(AXGN.US$
looks like more 💰flow and narrower loss this years looks interesting here
looks like more 💰flow and narrower loss this years looks interesting here
Read more